Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, which is more or less 9.11 % above the present share price of $76.07.

Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the earliest quarter of 2021.

The current consensus among eleven TipRanks analysts is for a reasonable Buy rating of shares in CVS Health, with an average price aim of eighty four dolars.

The analysts priced targets range from a high of hundred one dolars to a low of $61.

From the newest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is actually $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is presently ranked with 4 stars on a 0 5 stars ranking scale, with an average return of 11.5 % as well as a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management strategies. The Long or retail Term Care segment has offering of prescription medications as well as assortment of general merchandise.

The Health Care Benefits segment offers quite traditional, consumer-directed and voluntary health insurance products and associated services, which includes medical, pharmacy, dental, behavioural health, healthcare relief abilities. The Corporate segment involves in offering management and administrative services. The company was created by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.